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Internet-based guided self-help for glioma patients
with depressive symptoms: design of a
randomized controlled trial
Florien W Boele1*, Irma M Verdonck-de Leeuw2,3, Pim Cuijpers3, Jaap C Reijneveld4, Jan J Heimans4 and Martin Klein1
Abstract
Background: Among glioma patients, depression is estimated to be more prevalent than in both the general
population and the cancer patient population. This can have negative consequences for both patients and their
primary informal caregivers (e.g., a spouse, family member or close friend). At present, there is no evidence from
randomized controlled trials for the effectiveness of psychological treatment for depression in glioma patients.
Furthermore, the possibility of delivering mental health care through the internet has not yet been explored in this
population. Therefore, a randomized controlled trial is warranted to evaluate the effects of an internet-based,
guided self-help intervention for depressive symptoms in glioma patients.
Methods/design: The intervention is based on problem-solving therapy. An existing 5-week course is adapted for use
by adult glioma patients with mild to moderate depressive symptoms (Center for Epidemiology Studies Depression
Scale score ≥12). Sample size calculations yield 126 glioma patients to be included, who are randomly assigned to either
the intervention group or a waiting list control group. In addition, we aim to include 63 patients with haematological
cancer in a non-central nervous system malignancy control group. Assessments take place at baseline, after 6 and
12 weeks, and after 6 and 12 months. Primary outcome measure is the change in depressive symptoms. Secondary
outcome measures include health-related quality of life, fatigue, costs and patient satisfaction. In addition, all patients
are asked to assign a primary informal caregiver, who does not participate in the intervention but who is asked to
complete similar assessments. Their mood, health-related quality of life and fatigue is evaluated as well.
Discussion: This is the first study to evaluate the effects of problem-solving therapy delivered through the internet as
treatment for depressive symptoms in glioma patients. If proven effective, this treatment will contribute to the mental
health care of glioma patients in clinical practice.
Trial registration: Netherlands Trial Register NTR3223
Keywords: Glioma, Brain tumor, Depression, Quality of life, Internet-based treatment, Informal caregiver
Background
Patients with gliomas, primary brain tumors originating
from glial tissue, are not only faced with the diagnosis of a
life-threatening disease, but also with various neurological
symptoms [1,2]. Glioma patients often suffer from head-
aches [3-5], cognitive deficits, paresis, visual-perceptual
deficits, sensory loss, and seizures [1]. In addition,
depression is common in glioma patients. During the
first 8 months following the diagnosis, 15 to 20% of gli-
oma patients become clinically depressed [6,7]. Longitu-
dinal studies show that the prevalence of depression
among these patients keeps increasing up to one year
after surgery [8]. Surprisingly, glioma patients not only
seem to be at increased risk compared with the general
population (12-month prevalence 6.6%), but also compared
with other cancer patient populations [9,10]. This may
affect not only patients, but also their direct environ-
ment, including their spouses, family members, and
close friends. In fact, glioma patients’ neuropsychiatric
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status, including depressive symptoms, was found to in-
fluence the presence of depressive symptoms in significant
others [11]. These mental health issues can contribute sig-
nificantly to a decrease in significant others’ health-related
quality of life (HRQOL) [12,13].
The precise cause of depression in glioma patients re-
mains unclear. A number of mechanisms, including tumor
location, elevated intracranial pressure, and biochemical
changes may contribute to the development of depression
[14]. Evidently, the patient’s emotional reactions to the
diagnosis can contribute. Patients can experience shock
and disbelief, dysphoria, despair, anger and anxiety, and
intrusive thoughts about their diagnosis [15]. These issues
may cause an adjustment disorder to the situation, which
if persistent, can become a major depressive episode [16].
However, evidence for this theory is inconclusive as
awareness of the prognosis is not always associated with
mood disorders [17]. Moreover, these mechanisms occur
in other cancer patient populations as well, which only
emphasizes the unexpectedly high prevalence of depres-
sion among glioma patients, specifically.
While the etiology of this problem is not fully known,
it is clear that the above mentioned contributing factors
may impede the diagnosis of depression in glioma patients
[18]. For example, the mood problems can be interpreted
by treating physicians as ‘understandable’ considering the
circumstances, and this may complicate communication
about these symptoms [19]. The depression is then less
likely to be recognized, which can lead to an underdiagno-
sis, and subsequently to an undertreatment, of depression
[20]. This process can have serious negative consequences
for glioma patients as in this population, depression has
been associated with increased morbidity and even with
poorer survival [21,22]. Moreover, depression is the most
important independent predictor of HRQOL in patients
with brain tumors [23].
If this potentially treatable condition is recognized, the
treatment usually consists of the combination of antide-
pressants and intensive psychological treatment, such as
cognitive behavioral therapy (CBT) [24,25]. Both pharma-
cological and psychological treatment can encounter prob-
lems in glioma patients specifically. Glioma patients often
take multiple medications concurrently, which increases
the risk for drug interactions and may lead to a reluctance
to try antidepressants. For example, one study shows that
only 60% of patients in whom the treating physician recog-
nized depression, actually received antidepressants [26],
and it is unclear if the remaining 40% of depressed patients
received an alternative treatment such as psychotherapy.
Treatment with psychotherapy can encounter problems
as well, as psychotherapy usually requires good cognitive
functioning in order for a patient to benefit most while ap-
proximately 80% of brain tumor patients experience cogni-
tive deficits to some degree [1]. Therefore, while treatment
for depression has been shown effective in both the general
population [27,28] and in cancer patients [29], it remains
to be seen if either antidepressants or psychotherapy are
equally effective in glioma patients.
Problem-solving therapy (PST), a form of CBT, may
prove helpful in alleviating depressive symptoms espe-
cially in this patient population, as it is a brief and prac-
tical approach. Depression is linked with stressful life
events, and when depressed, patients may be less able to
actively cope with these stress inducing factors. In PST,
it is assumed that depressive symptoms are caused by
everyday problems that can be resolved with problem-
solving techniques. Resolution of problems then leads to
a reduction in depressive symptoms. By teaching more
adequate coping strategies, and aiding in the acceptance
of problems that cannot be solved [30], PST can prove
effective [31,32]. Indeed, it has been suggested as the
preferred treatment in depressive patients with somatic
disease [33].
During their disease trajectory, glioma patients frequently
have to visit the hospital. In a subset of patients who
suffer from neurological sequelae that affect their phys-
ical functioning and mobility (e.g. paresis, paralysis, epi-
lepsy, fatigue), face-to-face treatment for depression may
lead to additional burden. Alternative ways of delivering
PST, such as through the internet, may therefore become
more appealing. This may especially be the case in the
Netherlands, where in 2013, approximately 95% of all
households has internet access [34]. Internet-based psy-
chological interventions, including PST, have already been
found to be equally effective as face-to-face treatment
[27,35]. These internet-based programs make use of self-
help, where patients work through a standardized psycho-
logical treatment independently, sometimes guided by a
coach. This way, the interventions are thought to pose
low thresholds for participation, as it is more anonym-
ous, easily accessible as patients can work on the pro-
grams at a time of their choosing, and cost-effective as
only minimal involvement of health-care professionals
is necessary. As of yet, there is no scientific evidence
from randomized controlled trials available for the effect-
iveness of psychotherapy, whether internet-based or face-
to-face, in glioma patients [36]. Therefore, we presently
present the design of a randomized, controlled trial aimed
at alleviating depressive symptoms in glioma patients
using an internet-based guided self-help course. A second-
ary aim is to evaluate the effect of the intervention on
HRQOL of both patients and their significant others.
Methods/design
Design
This study is a randomized controlled trial evaluating the
effects of an internet-based guided self-help course for de-
pressive symptoms in glioma patients. We compare a group
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of patients who receive the intervention with a three month
waiting list control group and a non-central nervous system
malignancy control group. The intervention, which takes
approximately 5 weeks to complete, is aimed at patients
with mild to moderate depressive symptoms.
Assessments include self-reported outcomes completed
online. The assessments are scheduled at baseline (T0),
after completion of the online course (approximately
6 weeks after baseline; T1), 12 weeks after baseline (T2),
and 12 months after baseline, see Figure 1. Those in the
waiting list control group receive the same assessments,
but are also assessed after completion of the online course
(T3; approximately 6 weeks after T2), and 12 weeks there-
after (T4). Furthermore, patients with a high-grade malig-
nancy undergo an additional assessment at 6 months after
baseline (T3 or T5), as is also depicted in Figure 1. This
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study is performed in accordance with the Declaration of
Helsinki.
This study is approved by the institutional review board
of the VU University Medical Center (IRB00002991). Due
to the internet-based nature of the intervention and the
assessments, this approval is deemed sufficient for nation-
wide recruitment.
Study population
Adult (>18 years of age) WHO grade II, III or IV glioma
patients with mild to moderate depressive symptoms
(Center for Epidemiological Studies Depression Scale [37]
(CES-D) score ≥12) are invited to participate. After screen-
ing, patients scoring above 16, the usual cut-off score for
depression on the CES-D, subsequently receive the full
study information. Those scoring between 12 and 16 are
informed of their relatively low score and are given the op-
tion to receive the full study information or not.
For the non-central nervous system oncology control
group, adult (>18 years of age) patients with non-Hodgkin
lymphoma (NHL), chronic lymphatic leukaemia (CLL),
multiple myeloma (MM), or a myelodysplastic syndrome
(MDS) who have mild to moderate depressive symptoms
(CES-D score ≥12) are invited to participate. Here, too,
those patients scoring between 12 and 16 on the CES-D at
the time of screening are informed of their relatively low
score and they are asked if they want to receive full infor-
mation of the study or not.
Although not a strict requirement for participation, all
patients are additionally asked to invite an informal care-
giver to participate in the study. This refers to a significant
other who provides the majority of mental and physical
support to the patient. These informal caregivers do not
participate in the intervention but are asked to complete
the same assessments at the same time points concerning
their own mood, HRQOL, fatigue, etc.
Potential participants are excluded if they have no ac-
cess to the internet and/or no email address, if they have
insufficient proficiency of the Dutch language, and if
they express suicidal intent. Suicidal intent is screened for
with the Beck Scale for Suicide Ideation (BSS) [38]. If pa-
tients have a score higher than 0 on the BSS, a board certi-
fied psychologist (MK) conducts an interview through
telephone to assess the severity of symptoms. If a patient
is excluded due to suicidal intent, the general practitioner
is always contacted to assure proper referral to health care
professionals.
Recruitment and inclusion procedure
Patients are recruited through advertisements and news
items on websites frequently visited by glioma patients
and haematological patients. Patient associations are asked
for help in spreading study information through their web-
sites, newsletters and meetings. Treating physicians and
nurse practitioners throughout the Netherlands collabor-
ate in this study by providing information brochures to
their patients. These professionals are contacted through
the intermediary of the Dutch Society for Neuro-Oncology
and the Dutch Neurology Association, as well as through
the authors’ personal networks.
The advertisements, news items and information bro-
chures contain a link to a website with an online screening
procedure. If interested, patients complete this online ques-
tionnaire that contains questions on basic demographic
information (age, gender, level of education), contact in-
formation, and the BSS and CES-D. On this website, it is
explained that by completing the questionnaire, patients
give permission to contact their general practitioner if the
researchers deem this necessary. Furthermore, they are
made aware that the personal information they provide
will only be used if they later decide to take part in the
study and sign informed consent forms.
Eligible patients receive an information letter. Within
a week the study coordinator (FWB) contacts the eligible
patients by telephone to answer possible questions. Sub-
sequently, they are asked to sign the informed consent
form they received with the information letter. They are
also asked to sign a form enabling the researchers to re-
quest information on the patient’s disease and treatment
at their treating hospital. Figure 2 illustrates this recruit-
ment procedure. After informed consent is obtained, both
the general practitioner and the treating physician are in-
formed about the patient’s intent to participate in the trial.
Randomization
Glioma patients are randomly assigned to either the inter-
vention group or the waiting list control group after com-
pletion of the baseline assessment (T0). An adaptive simple
randomization technique is employed to minimize the
chance of imbalanced group sizes.
Intervention
The internet-based guided self-help intervention is based
on the principles of problem solving therapy. The original
intervention, ‘Everything under control’ (“Alles onder con-
trole”) has been shown to have significant positive effects
on depression, anxiety and stress/burnout in a randomized
controlled trial with 215 adults from the general popula-
tion [39]. With small changes, this online intervention is
adapted for use by glioma patients and patients with haem-
atological malignancies. Modifications concern additional
information about the specific diseases and their treatment,
and the psychological impact on everyday life. Examples of
participants’ assignments are made disease-specific.
The intervention consists of 5 modules with text and
exercises. Patients are asked to complete one module a
week and spend a minimum of two hours a week on their
exercises. During the intervention, patients describe what
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they feel is important in their lives, make a list of their
problems and concerns, and divide these into three cat-
egories: 1) unimportant problems (problems that are not
related to what is important in their life), 2) important and
solvable, and 3) important but unsolvable. For each of
these problems the patient makes a plan on how to cope
with this, guided by methods explained in the modules.
The participants receive feedback on the exercises from a
personal coach within three working days after comple-
tion of the assignment. The coach is not a therapist, but
only supports the patient in working through the inter-
vention. Participants can always contact their coach for
additional support through the website. The coaching is
provided by one of the researchers (FWB), by trained and
supervised students in the final phase of a Master’s pro-
gram in Psychology or by specialists from Prezens. In col-
laboration with the VU University medical center, Prezens
provides psychological care and support.
The glioma patients in the waiting list control group
are offered the same intervention after completion of the
12 weeks follow-up (T2).
Outcome measures
Self-report measures of depressive symptoms, HRQOL,
fatigue, costs and patient satisfaction are presented on-
line in a fixed order. Patients are allowed to return to
any of the measures for review or changes during an
assessment.
Primary outcome measure
The primary outcome measure is the change in depres-
sive symptoms as measured with the CES-D [37]. This
questionnaire is designed to measure depressive symp-
toms in the general population (i.e., persons older than 18,
without psychiatric disease). The 20-item scale measures
the major components of depressive symptomatology, in-
cluding depressive mood, feelings of guilt and worthless-
ness, psychomotor retardation, loss of appetite, and sleep
disturbance. Participants are asked to indicate if they feel
a particular item is applicable to their situation of the past
week, on a 4-point scale. Scores range between 0 and 60,
with higher scores indicating more depressive symptoms.
In the general population, the usual cut-off score for de-
pression is ≥16. Within cancer patients, the CES-D has
yielded good psychometric properties, with good con-
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the current intensity of the patients’ specific attitudes,
behaviors, and plans to commit suicide during the past
week. The first 19 items consist of three options graded
according to the intensity of the suicidal intent and rated
on a 3-point scale ranging from 0 to 2. These ratings are
then summed to yield a total score, which ranges from 0
to 38. The last two items assess the number of previous
suicide attempts and the seriousness of the intent to die
associated with the last attempt. In this study, only the
first 19 items are administered. If the patient reports any
active or passive desire to commit suicide on the first 5
screening items, then the additional 14 items are admin-
istered as well.
Health-related quality of life (SF-36 and EQ-5D)
HRQOL is assessed by means of the Short-Form Health
Survey (SF-36) [41]. The SF-36 is composed of 36
items, organized into 8 multi-item scales assessing: (1)
physical functioning; (2) role functioning-physical; (3)
role functioning-emotional; (4) pain; (5) vitality; (6) social
functioning; (7) mental health; and (8) general health per-
ceptions. Scores range from 0-100. Furthermore, two
higher-order summary scores can be computed – one for
physical health (Physical Component Summary) and one
for mental health (Mental Component Summary). On
these scales, scores have a mean of 50 and a standard devi-
ation of 10 based on data from the general population.
In addition, the EuroQol (EQ-5D) [42] is administered.
This is a standardized, non-disease specific instrument
assessing HRQOL. With 5 items scored on a 3-point Likert
type scale, the EQ-5D measures mobility, self-care, usual
activities, pain/discomfort and anxiety/depression.
Brain tumor-specific HRQOL (EORTC BN20)
For glioma patients, a supplementary questionnaire module
is employed to assess additional health problems associated
specifically with brain tumors and their treatment. The
EORTC Brain Cancer Module (BN20) [43] is organized
into multi-item subscales assessing future uncertainty, vis-
ual disorders, motor dysfunctions, and communication def-
icits. The remaining 7 items assess other disease symptoms
and side-effects of treatment found to be prevalent among
patients with brain tumors, including headaches, seizures,
drowsiness, hair loss, itching, weakness in the legs, and lack
of bladder control. The scores range from 0-100, with
higher scores indicating more symptoms.
Fatigue (CIS)
Fatigue and fatigue related symptoms are measured with
the Checklist Individual Strength (CIS) [44]. The CIS is a
multidimensional fatigue scale; it measures fatigue severity
(8 items), concentration problems (5 items), reduced mo-
tivation (4 items), and reduced activity (3 items). Each
item is scored on a seven-point Likert scale. Total scores
of every subscale are obtained by adding the individual
items, with high scores indicating a high level of fatigue, a
high level of concentration problems, low motivation, and
a low level of activity. Based on data from patients with
chronic fatigue syndrome, patients with a score of >35 on
the fatigue severity subscale are considered to be severely
fatigued.
Cognitive functioning
Patient’s self-reported cognitive functioning is rated by
the scale developed for use in the Medical Outcomes
Study [45]. This 6-item scale assesses day-to-day problems
in cognitive functioning including difficulty with reasoning
and problem solving, slowed reaction time, forgetfulness,
and problems with concentration (range 1-6).
Costs (TIC-P)
Costs in terms of health care utilization and production
loss are assessed with the Trimbos/iMTA questionnaire
for Costs associated with Psychiatric Illness (TIC-P) [46].
This questionnaire consists of two parts; part 1 covers the
direct costs of care utilization of participants (15 items),
and part 2 is used to determine indirect costs that result
from production loss associated with the psychiatric
symptoms. Here, the Short Form Health and Labor Ques-
tionnaire [47] is incorporated. This questionnaire contains
three modules that assess the absence from paid employ-
ment, production loss without absence from paid employ-
ment, and impediments to paid or unpaid employment.
Patient satisfaction
During the post-intervention assessment (T1 or T3), the
patients’ experience with the online course is evaluated.
A short study-specific questionnaire evaluating the usabil-
ity, readability, course content, and self-perceived useful-
ness of both the online course and the feedback provided
by the coach is presented along the other questionnaires.
Room for remarks is provided as well.
Statistical analyses
Appropriate parametric and non-parametric statistical tests
will be employed to examine differences between the
groups in terms of all relevant demographic and clinical
variables at baseline. Missing observations at follow-up will
be imputed using the multiple imputation procedure [48].
Following the CONSORT guidelines, the intention-to-treat
principle will be applied. All randomized participants will
be included in the analyses, regardless of how many treat-
ment modules or sessions they complete. Within-group
and between-group differences (e.g., patients with or with-
out epileptic seizures, pain, neurological deficits, or self-
reported cognitive deficits) in dependent variable scores will
be analyzed using both univariate and multivariate statis-
tical techniques. For between-group statistical comparisons,
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sociodemographic variables (age, gender, and education)
will be used as covariates, where necessary. The effects
of the interventions will be tested by means of Helmert
contrasts. Relative improvements in depressive symptoms
(CES-D score) in the experimental group compared with
pre-treatment assessment as well as both control groups
will be calculated using Cohen’s d. If the primary outcome
measure is non-normally distributed, the test and the 95%
confidence intervals will be based on robust standard
errors and/or on non-parametric bootstrap techniques.
This will help to correctly ascertain the relative effective-
ness of the treatment over the control conditions.
Sample size
The effect of the intervention on symptoms of depression
is the primary outcome measure and this is used as start-
ing point for the sample size calculations. Based on previ-
ous experience with this intervention in adults, we expect
a Cohen’s d of 0.50. Assuming an alpha of 0.05 and a stat-
istical power (1-beta) of 0.80, we need 50 patients in each
condition. Allowing for a dropout percentage of 25% once
included, we aim to recruit 126 glioma patients (63 per
group) and 63 patients with haematological malignancies
in total.
Discussion
In this paper, we describe the study design of a random-
ized controlled trial aimed at evaluating the effects of an
internet-based, guided self-help intervention for depres-
sive symptoms in glioma patients. This study is innova-
tive in two ways: 1) as of yet, there is no evidence from
RCTs for the effectiveness of psychotherapy in glioma
patients with depressive symptoms; and 2) to our know-
ledge, providing psychosocial care through the internet
has not been explored in the depressed glioma patient
population until now.
We expect the external validity of this study to be high,
as we employ only few exclusion criteria. Any adult WHO
grade II, III or IV glioma patient at any disease stage with
mild depressive symptoms is invited to participate in the
trial to try and relief these symptoms. Furthermore, as the
intervention is administered through the internet and pa-
tient inclusion is organized nation-wide, we should be able
to reach a large group of potential participants. Using the
internet also evidently has its downsides. For certain pa-
tients, such as those unaccustomed to using the computer
in their everyday lives or those with more severe cognitive
impairment, using the internet may prove more difficult
and could possibly result in non-participation or dropout
of the study. We aim to construct the website in a very
straightforward and easy-to-use way, in order to minimize
this possibly negative effect. In addition, both interventions
using the internet and self-help interventions are prone to
high dropout rates [49], suggesting that this problem could
occur in our trial as well. Therefore we present the online
questionnaires separately from the intervention website,
and email reminders are sent for both the assessments
and the course assignments separately. Moreover, if par-
ticipants do not respond to these reminders, we try and
contact them through telephone instead. This should
strengthen the relationship between the participants and
the researchers substantially, thereby possibly improving
patient participation throughout the trial [50].
Our frequent follow-up assessments, up until 12 months
after the guided self-help course, enable evaluation of both
short- and long-term effects of the intervention. However,
frequent evaluation of mental well-being through self-
reported questionnaires may also lead to patients’ increased
awareness of their depressive symptoms. To minimize this
possible effect we keep track of the patients’ suicidal idea-
tion and depressive symptoms throughout follow-up and
we will contact both the participant and their general prac-
titioner in case symptoms worsen significantly.
Due to its nationwide design, our study could raise
awareness of depressive symptoms among both physicians
and patients. Whereas this is favorable for patients, it may
lead to a risk of contamination in this randomized con-
trolled trial, as more psychological help may be offered
outside of the intervention offered in our study. However,
the TIC-P assessment records all contact with health-care
professionals, so with adequate power we will be able to
correct for this in the analyses.
In conclusion, we currently present the design of our
study aimed at improving symptoms of depression in gli-
oma patients using a brief internet-based guided self-help
intervention based on the principles of PST. This can pro-
vide methodological clarity and can aid and encourage
further research efforts to improve mood and HRQOL in
glioma patients. Our randomized controlled trial is ex-
pected to contribute substantially to the existing literature
as there is a hiatus in studies evaluating the effectiveness
of different treatments for depression, as well as interven-
tions delivered by means of the internet in this patient
population. Furthermore, implementation in clinical prac-
tice should be relatively easy to accomplish if our inter-
vention proves to be effective, as it only requires minimal
involvement of health care professionals. Currently, this
trial is in the recruitment phase.
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